Navigation Links
Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay
Date:12/14/2007

After more than 8 years of follow-up, older women taking the newer drug fared better, study finds

FRIDAY, Dec. 14 (HealthDay News) -- The aromatase inhibitor drug Arimidex continues to outpace the old standard tamoxifen when it comes to preventing recurrences of hormone-receptor-positive breast cancers in postmenopausal women.

Even three years after treatment was stopped, women taking Arimidex still saw a benefit, researchers said.

"It has been very good news," said Dr. Aman Buzdar, U.S. principal investigator of the ATAC (Arimidex or Tamoxifen Alone or in Combination) trial, the results of which were expected to be presented Friday at the 2007 San Antonio Breast Cancer Symposium.

"A lot more women receiving Arimidex are free of cancer compared to tamoxifen, and the 100-month data show that these differences, if anything, with time actually continued to increase -- meaning there were fewer and fewer recurrences on Arimidex compared with tamoxifen," Buzdar said.

"Arimidex is the standard of care for postmenopausal women with receptor-positive breast cancer," confirmed Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "One hundred months [over eight years] of follow-up is very profound. It's a true credit to the investigators to be able to do the study and have that much follow-up, and it shows that we have reached a new level of care for postmenopausal women. That's what I use and continue to use."

Hormone-receptor-positive cancers respond to circulating estrogen or progesterone. Experts estimate that from 50 percent to 70 percent of breast cancers are hormone receptor positive.

The new findings were also expected to be published in the journal The Lancet Oncology to coincide with the presentation.

Arimidex (anastrozole) is an aromatase inhibitor, a relatively new class of compounds that blocks estrogen production in the
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
2. Study: HPV test beats Pap in detecting cervical cancer
3. Ultrasound Beats Blood Test for Gauging Ovarian Cancers: Study
4. Honey Beats Meds at Soothing Kids Cough
5. Tamoxifen Helps Treat Bipolar Disorder
6. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
7. FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named Walker in the United States
8. Statins reduce loss of function, keeping old lungs young - even in smokers
9. Random drug testing not reliable in keeping teen athletes from using
10. Tips for Keeping Food Portions Under Control, from Harvard Womens Health Watch
11. Is fear of gaining weight keeping many women from trying to quit smoking?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay
(Date:6/30/2015)... ... 2015 , ... Lecrae is quickly developing into one of the biggest music ... New York Times to Billboard Magazine and Variety, among others. His transparency and ... why so many people are taking notice. , “We are very excited about this ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... be held October 28-31, 2015 at Disney’s Coronado Springs Resort in Lake Buena ... and networking. Each year, this premiere event for psychiatric-mental health nursing draws more ...
(Date:6/30/2015)... ... 2015 , ... Izenda is proud to acknowledge the hard ... an accredited American educational institution through its scholarship program. , In today's Age ... environment, political campaigns, and a variety of other worldwide trends. Modern day technology ...
(Date:6/30/2015)... ... June 30, 2015 , ... Americans report feeling more ... buzzer on Monday mornings, which puts stressed out people right over the edge. ... 22% suffering from sleep deprivation every night. Sleeping pills now lead the list of ...
(Date:6/30/2015)... ... June 30, 2015 , ... Scott Purdy, the spokesperson for ... Provider XO. Scott Purdy stated that the XO stands for eXtra Operability (XO) which ... the workflow processes of the Revenue Cycle. , Provider XO, based in Cleveland ...
Breaking Medicine News(10 mins):Health News:Hands of Hope to Present Grammy Award-Winner Lecrae in Concert this August 2Health News:Hands of Hope to Present Grammy Award-Winner Lecrae in Concert this August 3Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 2Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 3Health News:Izenda Offers Embedded BI and Analytics Scholarship 2Health News:Izenda Offers Embedded BI and Analytics Scholarship 3Health News:Wake UP Happy and Sleep Soundly with Famous Experts with My Wake UP Call® Motivational Alarm Clock® Messages and My Good Night Messages™ - Now Available at Audible! 2Health News:Wake UP Happy and Sleep Soundly with Famous Experts with My Wake UP Call® Motivational Alarm Clock® Messages and My Good Night Messages™ - Now Available at Audible! 3Health News:Dephinitive Systems Is Getting a New Name 2
... a third of American,adults take some type of multivitamin ... is better health, even though there is no firm ... one thing, but the presence of,harm is another: A ... concluded that there was an increased prostate cancer risk ...
... to Stethoscope, the distinguished public lecture series organized by ... (MUHC), is embarking on a second season. "Again this ... on a journey into a possible future, when current ... declared Dr. Arthur T. Porter, Director General of the ...
... The Russell,Investment Group has advised Protalix Biotherapeutics ... float weight adjustment effective after the close of,trading ... Russell 2000,Russell 2000 Growth, Russell 2500, Russell 2500 ... Growth, Russell Small Cap,Completeness and the Russell Small ...
... Sept. 28 Transcept,Pharmaceuticals, Inc., a specialty pharmaceutical ... drugs, today announced,that Glenn A. Oclassen, President and ... 2007 BIO Investor Forum at the Palace Hotel ... 3:00 PM Pacific Time. About Transcept Pharmaceuticals ...
... Doctors need to be more proactive in diagnosing the condition, ... in seven women suffers from depression before, during or after ... can be devastating to the mother, her baby and her ... of The American Journal of Psychiatry . , ...
... M. Williams Speak Out on Mental Health Crisis,Facing ... Experts in mental,health, Members of Congress and other ... Caucus Foundation,s 2007 Annual,Legislative Conference to shed light ... Needs." Rep. Julia Carson (D - IN) together,with ...
Cached Medicine News:Health News:Excessive Multivitamin Use May Raise Risk for Prostate Cancer, from Harvard Men's Health Watch 2Health News:Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment 2Health News:15% of Women Struggle With Pregnancy-Related Depression 2Health News:15% of Women Struggle With Pregnancy-Related Depression 3Health News:Black America Urged to Confront Its Secret Pain: Depression 2Health News:Black America Urged to Confront Its Secret Pain: Depression 3Health News:Black America Urged to Confront Its Secret Pain: Depression 4Health News:Black America Urged to Confront Its Secret Pain: Depression 5
(Date:6/30/2015)... June 30, 2015  Today, the National Mobility Equipment ... 2015 National Mobility Awareness Month Local Heroes Contest on ... online entries that received 1.3 million votes. The sponsors ... Toyota Mobility , and Valley Honda Dealers ... and Vantage Mobility International (VMI) and ...
(Date:6/30/2015)... Calif. , June 30, 2015  Avanir ... PRISM II study showing that treatment with NUEDEXTA ... reduction in symptoms of pseudobulbar affect (PBA) in ... PBA is a distressing condition characterized by sudden ... from certain neurologic diseases or brain injury. PRISM ...
(Date:6/30/2015)... Minn. , June 30, 2015  EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering  of 40,229,886 units. Each ... of a Series A warrant to purchase one share ... warrant to purchase one share of common stock, at ...
Breaking Medicine Technology:NMEDA Announces National Contest Winners 2NMEDA Announces National Contest Winners 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3